GlassScriptPhysician profile
Denise D Robinson
NPI 1033691118
$1,004.58
in general payments reported to CMS, 2019-2025
22 companies · $30.32 in 2025
The $30.32 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $254 · 2023: $363 · 2024: $357 · 2025: $30.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.01 | 2022-2024 | Xarelto |
| Lilly USA, LLC | $114.23 | 2022-2023 | Trulicity, Mounjaro, Jardiance |
| Insulet Corporation | $79.75 | 2023-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.46 | 2022-2023 | Jardiance, Synjardy |
| Ironwood Pharmaceuticals, INC | $67.48 | 2022-2023 | Linzess |
| Collegium Pharmaceutical, INC. | $58.81 | 2023-2024 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.89 | 2023-2024 | Relistor |
| Fidia Pharma USA INC. | $46.11 | 2024 | Triluron, Hymovis, Hyalgan |
| Abbvie INC. | $40.05 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $36.94 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $35.07 | 2022-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $33.57 | 2023 | Belsomra, Steglatro |
| Braeburn INC. | $27.40 | 2024 | Brixadi |
| Novo Nordisk INC | $25.00 | 2023 | Rybelsus |
| Boston Scientific Corporation | $23.42 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $18.81 | 2024 | Sublocade |
| Athena Bioscience, LLC | $17.31 | 2024 | Qdolo |
| Mylan Specialty L.P. | $16.66 | 2022 | |
| Glaxosmithkline, LLC. | $16.44 | 2022 | |
| Virtus Pharmaceuticals LLC | $14.81 | 2023 | Levorphanol Tartrate |
| Novartis Pharmaceuticals Corporation | $14.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.